A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors

Recruiting

Phase 1

Phase 2

Sponsor:

AstraZeneca

Code:

NCT06188520

Conditions

ER+ HER2- Advanced Breast Cancer

High-grade Serous Ovarian Cancer (HGSOC)

Eligibility Criteria

Sex: Female

Age: 18+

Healthy Volunteers: Not accepted

Interventions

AZD8421

Camizestrant

Ribociclib

Palbociclib

Abemaciclib

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information